Regeneron Pharmaceuticals, Inc.
805.02USD
-14.0700 (-1.72%)
Computing valuation metrics…
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on REGN.
Valuation
P/E (TTM)
19.15x
P/E (Forward)
12.84x
EV/EBITDA
17.18x
EV/Revenue
4.83x
P/S (TTM)
5.34x
P/B
2.61x
FCF Yield
4.54%
Dividend Yield
0.47%
Gross Margin
37.68%
Operating Margin
24.74%
Net Margin
27.86%
Peer Comparison — Biotechnology
| Company | Mkt Cap | P/E | EV/EBITDA | FCF Yield | Rev Growth | Div Yield |
|---|---|---|---|---|---|---|
| REGNRegeneron Pharmaceuticals, Inc. | $82.88B | 19.15x | 17.18x | 4.54% | 16.73% | 0.47% |
| VRTXVertex Pharmaceuticals Incorporated | $132.71B | 30.51x | 24.88x | 1.98% | 12.50% | 0.00% |
Subject metrics from SEC filings where available; peer metrics from cached market data.
| $79.89B |
| — |
| — |
| 0.37% |
| 2.10% |
| 0.00% |
| ARGXargenx SE | $54.94B | 30.26x | 715.84x | — | 52.10% | 0.00% |
| RPRXRoyalty Pharma plc | $36.90B | 33.97x | 25.37x | -3.24% | 16.50% | 1.47% |
| ROIVRoivant Sciences Ltd. | $26.36B | — | — | -4.24% | -33.50% | 0.00% |
| INCYIncyte Corporation | $23.45B | 14.74x | 9.76x | 5.03% | 37.70% | 0.00% |
| BNTXBioNTech SE | $22.13B | — | — | -1.13% | -59.50% | 0.00% |
| ASNDAscendis Pharma A/S | $16.01B | 18.65x | 59.29x | 0.08% | 114.70% | 0.00% |